Objective: The use of estrogen and progesterone to manage vasomotor symptoms (ie, hot flashes and night sweats) has declined because of concerns about their risks, and there is an increased interest in alternate, effective, and low-risk treatments. This study reports the results of a randomized controlled trial of clinical hypnosis for treating vasomotor symptoms among postmenopausal women.
S everal meta-analyses and a Cochrane review indicate that additional clinical trials are needed to guide clinical practice decisions around the use of nonhormonal therapies for vasomotor symptoms (ie, hot flashes and night sweats). 1<4 Trials are needed to generate a sufficient evidence base to guide clinical treatment decisions concerning the use of nonhormonal therapies for vasomotor symptoms. As many as 80% of women experience vasomotor symptoms, and nearly 20% find them intolerable. 5 Sudden rushes of heat and sweating are often accompanied by increased heart rate, chills, shivering, clamminess, anxiety, feelings of nausea, a Bheadache[-like sensation, visible reddening and blotching of face and neck, increase in core body temperature, increased metabolism, and interrupted sleep. 6<18 Symptoms generally wane 5 to 7 years after menopause 19 but can persist in some women for more than 20 years, with a median symptom duration of approximately 4 years. 20 Alternate nonhormonal pharmacotherapy, such as clonidine, gabapentin, and paroxetine, seems promising, but adverse effects and cost can diminish long-term compliance.
Clinical hypnosis, a mind-body therapy designed to facilitate a hypnotic state, coolness, and control of symptoms, seems promising; however, no large-scale, randomized controlled trials have yet been published. Pilot data showed that breast cancer survivors who received five weekly sessions of clinical hypnosis experienced a 69% reduction in hot flashes relative to baseline. 21 These results are comparable to or greater than the results of open-label studies with paroxetine and venlafaxine. 4,22<25 Thus, the purpose of this randomized controlled trial was to evaluate clinical hypnosis against structured-attention control for the treatment of hot flashes in postmenopausal women. Primary outcomes were hot flash frequency (perceived and physiologically measured) and hot flash score (diary frequency Â severity). Secondary outcomes were hot flash interference, sleep quality, and treatment satisfaction.
METHODS

Study design
The study was conducted as a single-blind, randomized, clinical trial in central Texas evaluating the effectiveness of clinical hypnosis compared with active structured-attention control. The study was approved by the university institutional review board, and all participants provided a written informed consent form.
Participant selection
Women were recruited from December 2008 to April 2012 via newspaper advertisements, professional referrals, and television and billboard advertisements. Participants were eligible if they were postmenopausal, were 18 years or older, and had no menstrual period in the past 12 months or had no menstrual period in the past 6 months and either (a) had a medically documented history of a follicle-stimulating hormone level greater than 40 mIU/ml or (b) had undergone bilateral oophorectomy. Furthermore, participants were required to have a self-reported history of seven hot flashes per day at minimum (or 50 hot flashes per week) at baseline.
Participants were required to have discontinued estrogen/ progestinYcontaining products based on Food and Drug Administration draft recommendations for industry 26 : 1 week or longer for prior vaginal hormonal products (rings, creams, and gels), 4 weeks or longer for prior transdermal estrogenalone or estrogen/progestin products, 8 weeks or longer for prior oral estrogen and/or progestin therapy, 8 weeks or longer for prior intrauterine progestin therapy, 3 months or longer for prior progestin implants and estrogen-alone injectable drug therapy, and 6 months or longer for prior estrogen pellet therapy or progestin injectable drug therapy.
Women were excluded if they were receiving any other treatment of hot flashes or using any complementary or alternative medical treatments of vasomotor symptoms (including soy, black cohosh, phytoestrogens, and any other mind-body techniques). Participants were excluded from the study if they had a history of psychosis, borderline personality disorder, or serious psychopathology because these diagnoses are considered to be contraindications for clinical hypnosis.
Data collection
Potential participants were screened for eligibility by telephone. Women who met the eligibility criteria completed baseline measures, including the Hot Flash Symptoms Diary, 27, 28 physiological monitoring of hot flashes, and other secondary outcome measures. Random assignment was made by the study biostatistician from a confidential computer-generated list of permuted blocks of varying sizes. Participants were randomized by sealed envelope. The envelope was not opened by the research coordinator until the women had completed and provided their baseline data. Participants were scheduled for five weekly sessions of either clinical hypnosis or structured attention. Participants completed follow-up assessments on weeks 6 and 12. Participants were paid after three intervention or control sessions and at the final follow-up contact, for a possible total of US$300.
Treatment
The clinical hypnosis intervention followed a treatment manual and was delivered by therapists who were specifically trained in clinical hypnosis according to established training standards. 29 The clinical hypnosis intervention consisted of hypnotic inductions and instruction in the practice of self-hypnosis toward the therapeutic goals of reduction of hot flashes and improved sleep. 30<37 In each 45-minute session, participants were provided specific suggestions for mental imagery for coolness, safe place imagery, and relaxation (individualized based on the women's preference). Participants were also provided an audio recording of a hypnotic induction and tasked with the daily practice of self-hypnosis at home. Treatment fidelity and compliance were evaluated at each session by means of a checklist.
The structured-attention control condition, designed to match the clinical intervention in therapist exposure, therapeutic environment, interpersonal exchange, and encouragement, was used based on the recommendations for minimal-effect interventions. 38 Structured attention matched the hypnotic intervention in that it consisted of five sessions, where discussion of symptoms, attentive listening, interpersonal exchange, avoidance of negative suggestions, monitoring, measurement, and encouragement were provided in a therapeutic environment by a clinician trained to deliver the control intervention, using a standard structured-attention manual. However, no hypnotic inductions or cooling suggestions were provided. Each structured-attention session lasted approximately 45 minutes, and fidelity was determined by a checklist. Participants were given a CD that provided information about hot flashes and tasked with daily listening.
Measurements
Hot flash frequency and hot flash score were obtained using the Hot Flash Symptoms Diary. 27, 28 Participants recorded their hot flashes for 7 days by daily frequency and severity (mild, moderate, severe, and very severe), and the diary was administered at baseline, on weeks 2 to 6, and at 12-week follow-up. This instrument provides a measure of hot flash frequency and hot flash score (product of frequency Â severity).
A sternal skin conductance monitoring system was used to objectively measure hot flash frequency. The Biolog ambulatory recorder 39 recorded skin conductance levels using Biopac EL-507 silver/silver chloride electrodes for electrodermal activity and a 0.5 constant voltage circuit. 40 Electrodes are 1.0 cm in diameter and filled with 0.5% chloride solid gel. 41 Electrodes are attached 1.5 in. below the collar bones and 2 in. on either side of the sternal midline. The Biolog is programmed to sample 12-bit skin conductance data at 1 Hz (once per second). Customized software (FlashTrax, version 1.2; UFI, Morro Bay, CA) was used to evaluate hot flashes. Based on published norms, 10<13 hot flashes were flagged if there was an increase in sternal skin conductance of at least 2 Kmho within a 30-second period, with a 15-minute postevent lockout. Each skin conductance track was evaluated by a trained expert, verifying that each skin conductance event matched published norms for vasomotor events. Physiological monitoring of hot flashes was recorded for 24 hours at baseline, on week 6, and on week 12.
Secondary outcomes included measures of hot flash daily interference and sleep quality. To investigate the impacts of hot flashes on women's overall quality of life, we used the Hot Flash Related Daily Interference Scale in this study. 42 This measure has been shown to be internally consistent and valid. 42 Data from this instrument were collected at baseline, on week 6, and at 12-week follow-up. Participants were given the Pittsburgh Sleep Quality Index (PSQI) 43 at baseline, at 6-week follow-up, and at 12-week follow-up to investigate quality of sleep. Treatment satisfaction was assessed at 12-week follow-up using a 0 to 10 rating (0 = Fdissatisfied_ to 10 = Fcompletely satisfied_). Adverse events were assessed at each contact by women's self-reports, and events were logged and reported to the institutional review board.
Statistical analyses
Sample size was based on data from a pilot study that compared the hypnosis intervention to no-treatment control. 21 We estimated power calculations cognizant of the placebo effect in hot flash treatment literature, which reported effects of as large as a 30% reduction in hot flash frequencies and hot flash severity scores. 27, 28 Calculations were conducted using G*Power, which takes into account expected effect size, desired power, correlation between pretest and posttest main effects, and sphericity. 44 Given the effect size (d = 0.488) in pilot data, 21 an > of 0.05, and a power of 0.90, a total sample of 146 (73 in each arm) was determined.
The modified intention-to-treat analysis included all randomized participants who provided diary data, which were analyzed regardless of adherence to protocol. Where appropriate, data were assessed for normality and homogeneity. Missing data were accounted for using maximum likelihood imputation. 45, 46 To test primary outcomes, we performed two analyses of covariance (ANCOVA): one between-subjects factor (experimental condition) and one covariate (pretest). Perceived frequency and physiologically recorded frequency were analyzed separately. Analyses using a repeated measure (posttest and follow-up) were also conducted with the 12-week follow-up data to examine if the effects of the hypnosis intervention were maintained. Four separate analyses were conducted. The hypotheses associated with secondary outcomes were tested using a series of ANCOVA with pretest scores as covariate; follow-up data were analyzed with repeated-measures ANCOVA conducted using the SPSS statistical software package, version 19 (SPSS Inc., Chicago, IL).
RESULTS
From December 2008 to April 2012, 538 women were screened to determine eligibility upon entrance in the study. Of these, 88 women did not meet the minimal hot flash inclusionary criteria, 50 were not classified as postmenopausal, 55 were receiving other simultaneous treatments of hot flashes, 10 were excluded for prohibitive medical/psychiatric diagnoses, 2 were nonYEnglish speaking, and 146 were successfully screened but failed to arrive for their baseline measurements (Fig. 1) . The remaining 187 women, who were eligible, provided a written informed consent form and were randomized at their baseline appointment.
Groups were matched for age, race, marital status, education, onset of symptoms, and symptoms severity (Table 1 . The participants ranged in age from 39 to 75 years, with a mean age of 54.61 years. The sample was largely white (68.8% vs 78.7%), followed by African Americans (21.5% vs 11.7%) and Hispanics (6.5% vs 6.4%). Most of them were married (61.3% vs 69.1%), with educational level being normally distributed. There were no statistically significant betweengroups differences in onset of amenorrhea, menopausal symptoms, hot flashes, hot flash frequencies, and hot flash scores at baseline. Missing data accounted for less than 2% of the data analyzed and were prorated for incomplete diaries.
Change in frequency of hot flashes
Reductions in subjectively reported mean hot flash frequency from baseline to week 6 in the hypnosis intervention showed a mean reduction of 48.07 (63.87%) hot flashes from baseline as compared with a 6.95 (9.24%) reduction in controls ( participants in the structured-attention condition. The mean difference in hot flash frequency at 12-week follow-up was significant (P G 0.001; 95% CI, 36.15-49.67).
Change in hot flash scores
Mean reductions in hot flash score (a product of hot flash frequency Â hot flash severity) were 16.72 (71.36%) for the hypnosis group on week 6 from baseline as compared with 1.91 (8.32%) in controls (P G 0.001; 95% CI, 38.84-47.85; Fig. 2 ). At 12-week follow-up, participants in the hypnosis intervention reported a continuing reduction of 18.83 (80.32%) from baseline as compared with 3.53 (15.38%) in controls. Mean differences in hot flash scores at 12-week follow-up were significant between conditions (P G 0.001; 95% CI, 12.60-17.54).
Physiologically recorded hot flashes
There was a 4.26 (40.92%) mean reduction in physiologically monitored hot flashes at 6 weeks compared with baseline for the hypnosis intervention. Conversely, the structuredattention control condition showed a mean increase of 0.63 (+7%) monitored hot flashes. The mean difference was significant (P G 0.001; 95% CI, 2.30-5.91). At 12-week followup, the hypnosis intervention reported a further reduction of 5.92 (56.86%) physiologically monitored hot flashes from baseline compared with a 0.88 (9.94%) decrease from baseline in the control condition. The mean difference between the two conditions in the number of physiologically monitored hot flashes was significant (P G 0.001; 95% CI, 2.00-5.46; Fig. 3 ).
Hot flashYrelated daily interference
Hot flashYrelated daily interference was assessed using the Hot Flash Related Daily Interference Scale. In the clinical hypnosis intervention, there was a mean score reduction of 4.02 (69.02%) from baseline at 6 weeks, compared with a mean score reduction of 1.04 (18.08%) from baseline in the structured-attention control condition. The mean difference between groups was significant (P G 0.001; 95% CI, 2.37-3.47). At 12-week follow-up, the clinical hypnosis participants continued to improve, showing a mean score reduction of 4.82 (82.11%) from baseline as compared with the mean score reduction of 1.32 (22.96%) from baseline in the structuredattention control. The mean difference between the participants in the clinical hypnosis condition and controls was significant (P G 0.001; 95% CI, 2.74-4.02; Table 2 ). This suggests that participants who received clinical hypnosis had substantially reduced levels of hot flashYrelated daily interference after treatment, with levels continuing to fall at 12-week follow-up, as compared with the control condition, which showed modest improvement.
Sleep quality
To evaluate the quality of participants' sleep after the intervention, we evaluated the PSQI global score. In the clinical hypnosis intervention, participants reported a global score reduction of 5.59 (43.49%) on week 6 of the intervention, compared with a 1.04 (8.75%) reduction in the structuredattention control condition. The difference between the global scores of the two groups was significant (P G 0.001; 95% CI, 3.65-5.84; Table 2 ). On follow-up, the clinical hypnosis participants continued to improve, showing a reduction in global score of 6.27 (53.63%) from baseline as compared with a 1.23 (10.34%) reduction in the control condition. This suggests that, for participants in the clinical hypnosis intervention, there was substantial improvement in the quality of sleep after intervention, as compared with the structured-attention control, which showed very modest improvement.
Adverse events
Adverse events were assessed at each session by participant self-reports. Adverse events for this study consisted solely of 25 participants reporting mild skin irritation from the skin conductance monitor electrode adhesive, which required no medical intervention to resolve. There were no other reported adverse events, adverse effects, or unintended effects from the clinical hypnosis or the structured-attention control.
Participant satisfaction
Treatment satisfaction in this study was assessed via a rating scale of 0 to 10 (0 = Bhighly dissatisfied[ to 10 = Bhighly satisfied[). Generally, participants in both arms found the treatment pleasant. Treatment satisfaction was assessed at 12-week follow-up. The clinical hypnosis intervention group showed a high degree of treatment satisfaction (mean [SD], 9.33 [0.99] ). Satisfaction with structured attention was also positive (mean [SD], 7.09 [3.06] ). Participants in the clinical hypnosis intervention reported significantly greater levels of satisfaction (P G 0.001; 95% CI, 7.79-8.59).
DISCUSSION
Improvements of at least a 50% reduction in hot flashes and daily interference are considered clinically significant. 27, 28 As hypothesized, clinical hypnosis significantly reduced hot flashes in postmenopausal women relative to structuredattention controls. At 12-week follow up, reductions in hot flash frequency (74.16% vs 17.13%; P G 0.001) and hot flash score (80.32% vs 15.38%; P G 0.001) were observed. Also, as hypothesized, significant reductions were found between clinical hypnosis participants and structured-attention controls in indices of hot flash daily interference scores (82.11% vs 22.96%; P G 0.001) and sleep quality, as indicated by PSQI global scores (53.63% vs 10.34%; P G 0.001).
Physiologically recorded hot flashes also showed significant reductions in the clinical hypnosis participants compared with controls. To our knowledge, this is the first published study to demonstrate a significant reduction in physiologically measured hot flashes in response to a mindbody intervention. At 12-week follow-up, the hypnosis intervention resulted in a 56.86% reduction in physiologically monitored hot flashes from baseline, compared with a 9.94% decrease from baseline in the control condition, further adding to evidence on the intervention's effectiveness.
It has been reported that there is a substantial placebo effect on hot flash treatment. 47 Why the placebo effect on hot flash treatment is so substantial is unknown; however, supportive care or the act of maintaining a diary may be empowering to participants and thus provide some relief. 48 Although the results of the clinical hypnosis intervention in this trial exceeded the effect of supportive care and diary monitoring provided in the structured-attention control condition, the study has several limitations.
In clinical hypnosis, the mechanism of action to reduce hot flashes is unknown. Because hot flashes involve increases in heart rate, flashing, and sweating, hot flashes have been posited to be a result of autonomic dysfunction. 49 A theory suggesting that hot flashes may be a result of a decrease in parasympathetic tone has been proposed. 50 Notably, a link between hot flashes and cardiovascular risk has been reported, and this theory suggests that the cause may be a decrease in relative parasympathetic influence, as indicated by reductions in the high frequencies of heart rate variability. 51<54 A possible mechanism of action for clinical hypnosis could be that regular practice of clinical hypnosis improves parasympathetic tone, resulting in reduced hot flash symptoms. This is an empirical question that should be investigated through comparative heart rate variability analyses in subsequent studies.
A limitation of this study is that the results may not be generalized to all participants with hot flashes because some hot flashes occur at times other than during climacteric (eg, pregnancy, perimenopause). Owing to the nature of mindbody clinical trials, self-selection bias may confound the results of this study. Participants who are negatively predisposed to mind-body therapy, unable to make the substantial time commitments required of a clinical trial of this nature, or unwilling to provide initial hot flash diaries to determine eligibility may have influenced the results. This may suggest that these results might be best interpreted as being particularly relevant to women who are more open to mind-body therapy. It should also be noted that the sample in this study was largely white, and there is evidence to suggest that ethnic and cultural differences may contribute to perceived interference in the reporting of hot flash frequency and severity among postmenopausal women. 55 Treatment satisfaction in this study was assessed via a single question rated on a rating scale of 0 to 10. The mean score of 9.33 for the hypnosis intervention reflects a high level of satisfaction and suggests that the intention is likely to be well received in a clinical setting. The mean satisfaction score of 7.09 in the control group was expected to be lower because of disappointment after a minimal decrease in hot flashes.
The strengths of this study include its sample size, the active control condition, the absence of negative adverse effects, and the inclusion of physiological measures in diary reports of hot flashes.
CONCLUSIONS
Future studies should investigate exactly how clinical hypnosis reduces hot flashes and explore efficient methods of dissemination. Safe and effective alternate therapies are needed, 56 and clinical hypnosis reduced hot flashes in this study of postmenopausal women, although the mechanism of action is not yet understood.
